Metizolam

Summary

Metizolam, alternatively recognized as desmethyl etizolam, stands as a thienotriazolodiazepine, characterized by its status as the demethylated counterpart of the closely linked etizolam.

Identifiers

IUPAC name
CAS Number	40054-68-0
PubChem CID	12434325
ChemSpider	59207712
UNII	K1C6XI9LLX
ChEMBL	ChEMBL4782672
Chemical and physical data
Formula	C16H13ClN4S
Molar mass	328.82 g·mol−1

Legal status

After being offered as a designer drug, metizolam was designated as a controlled substance in Sweden on January 26, 2016.

FAQ

• What is Metizolam?
• Metizolam, also known as desmethyletizolam, is a thienotriazolodiazepine. It is the demethylated analogue of etizolam, a closely related compound.
• What are the effects of Metizolam?
• Metizolam is known for its sedative and anxiolytic (anti-anxiety) effects. It can induce relaxation and a sense of calm.
• Is Metizolam a controlled substance?
• Yes, Metizolam is classified as a controlled substance in several countries, including Sweden, where it was placed under legal control in January 2016.
• Is Metizolam legal in my country?
• The legal status of Metizolam can vary from country to country. It’s essential to check your local laws and regulations regarding its use, sale, and possession.
• Is Metizolam safe to use?
• The safety of using Metizolam has not been extensively studied. Like other designer benzodiazepines, it may have potential risks, including addiction, withdrawal symptoms, and adverse effects. It’s crucial to use such substances with caution and under the guidance of a medical professional if prescribed.
• Can I purchase Metizolam online?
• The availability of Metizolam can vary depending on your location and local laws. Online markets may offer such substances, but it’s essential to be aware of the legal implications of purchasing and using them.
• Are there any known side effects of Metizolam?
• As with many psychoactive substances, Metizolam may have side effects, including drowsiness, dizziness, and impaired coordination. It is essential to use it responsibly and be aware of potential side effects.
• Can Metizolam be used for medical purposes?
• Metizolam is not approved for medical use in most countries. Healthcare professionals typically prescribe benzodiazepines or related compounds for specific medical conditions.
• Is Metizolam habit-forming?
• Designer benzodiazepines like Metizolam can be habit-forming, potentially leading to dependence and withdrawal symptoms. Responsible and controlled use is advised to minimize these risks.
• What should I do if I suspect someone is abusing Metizolam?
• If you suspect that someone is abusing Metizolam or any other substances and experiencing adverse effects, it’s essential to encourage them to seek medical help and support. Substance abuse can be harmful, and professional assistance may be needed.

References

1. Weber K, Bauer A, Langbein A, Daniel H (20 September 1978). “Heteroaromaten mit anellierten Siebenringen, III. Umwandlung von Thienotriazolooxazepinen in Diazepine”. This German publication explores the conversion of thienotriazolooxazepines into diazepine compounds, shedding light on the chemical synthesis of these substances.
2. US 3904641, Nakanishi M, Tahara T, Araki K, Shiroki M, “Triazolothienodiazepine compounds”, issued 9 September 1975, assigned to Welfide Corp. This U.S. patent issued in 1975 discusses triazolothienodiazepine compounds, which are part of the chemical family to which metizolam belongs.
3. EP 0776892, Hiroshi K, Ehara Syuji E, Hideaki S, Moriwaki Minoru M, Kenichi O, “Thienylazole compound and thienotriazolodiazepine compound”, published 1997-06-04, assigned to Yoshitomi Pharmaceutical Industries, Ltd. This European patent from 1997 deals with thienylazole and thienotriazolodiazepine compounds, shedding light on the pharmaceutical applications and chemical properties of these substances.
4. EP 0315698, Moriwaki M, Abe M, Mikashima H, Tahara T, “Thieno(triazolo)diazepine compounds and medicinal application of the same”, published 1993-03-03, assigned to Yoshitomi Pharmaceutical Industries, Ltd. Another European patent from 1993, this document delves into the medicinal applications of thieno(triazolo)diazepine compounds, providing insights into their potential use in the pharmaceutical industry.
5. Moosmann B, Bisel P, Franz F, Huppertz LM, Auwärter V (November 2016). “Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines – an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam, and nitrazolam”. This study, published in the Journal of Mass Spectrometry, offers a comprehensive analysis of the designer benzodiazepines, including metizolam, and their in vitro metabolism, contributing to our understanding of these substances.
6. Kintz P, Richeval C, Jamey C, Ameline A, Allorge D, Gaulier JM, Raul JS (July 2017). “Detection of the designer benzodiazepine metizolam in urine and preliminary data on its metabolism”. Published in Drug Testing and Analysis, this study outlines the detection of metizolam in urine samples and provides initial information on its metabolic pathways.
7. “Desmethyletizolam”. New Synthetic Drugs Database. This database entry offers insights into desmethyletizolam, a chemical relative of metizolam, providing valuable information about its properties and potential uses.
8. “31 nya ämnen kan klassas som narkotika eller hälsofarlig vara” (in Swedish). Folkhälsomyndigheten. November 2015. This Swedish source discusses the classification of 31 new substances as narcotics or potentially hazardous goods, which may include designer drugs like metizolam.